Profile data is unavailable for this security.
About the company
Intuitive Surgical, Inc. develops, manufactures and markets the da Vinci surgical system and Ion endoluminal system. The Company's da Vinci products are offered in categories, including da Vinci Surgical Systems, da Vinci instruments and accessories, da Vinci Stapling, da Vinci Energy, and da Vinci Vision, including Firefly Fluorescence imaging systems (Firefly) and da Vinci Endoscopes. It also provides a comprehensive suite of services, training, and education programs. It manufactures a set of instruments, which incorporates EndoWrist technology with wristed joints for natural dexterity and tips customized for various surgical procedures. Its Ion endoluminal system is a robotic-assisted, catheter-based platform designed to navigate through very small lung airways to reach peripheral nodules for biopsies. The da Vinci Surgical System enables surgeons to operate while seated at an ergonomic console viewing a three-dimensional, high definition (3DHD) image of the surgical field.
- Revenue in USD (TTM)5.16bn
- Net income in USD1.62bn
- Incorporated1995
- Employees8.08k
- LocationIntuitive Surgical Inc1020 Kifer RdSUNNYVALE 94086-5301United StatesUSA
- Phone+1 (408) 523-2100
- Fax+1 (408) 523-1390
- Websitehttps://www.intuitivesurgical.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Boston Scientific Corporation | 11.20bn | 526.00m | 63.18bn | 38.00k | 120.65 | 3.96 | 38.81 | 5.64 | 0.3678 | 0.3678 | 7.83 | 11.21 | 0.3613 | 2.55 | 7.15 | 294,657.90 | 1.88 | 3.03 | 2.13 | 3.78 | 66.45 | 69.70 | 5.21 | 7.17 | 1.31 | -- | 0.3636 | 0.00 | -7.66 | 5.80 | -119.23 | -- | 0.3484 | -- |
| Edwards Lifesciences Corp | 4.93bn | 1.46bn | 74.44bn | 14.90k | 51.68 | 14.50 | 46.85 | 15.11 | 2.31 | 2.31 | 7.78 | 8.24 | 0.6993 | 1.61 | 8.15 | 330,550.30 | 20.76 | 14.69 | 23.73 | 17.48 | 75.53 | 74.51 | 29.69 | 21.52 | 2.89 | -- | 0.1039 | 0.00 | 0.8809 | 11.96 | -21.56 | 10.72 | 30.77 | -- |
| Becton Dickinson and Co | 19.90bn | 1.87bn | 75.23bn | 72.00k | 41.14 | 3.12 | 18.36 | 3.78 | 6.37 | 6.37 | 67.88 | 84.04 | 0.3675 | 3.56 | 9.77 | 276,333.30 | 3.61 | 2.43 | 4.14 | 2.77 | 47.27 | 46.94 | 9.83 | 6.78 | 0.8506 | 7.40 | 0.4236 | 80.41 | -1.00 | 10.73 | -25.68 | 1.99 | 5.05 | 5.66 |
| Stryker Corporation | 16.25bn | 2.08bn | 102.96bn | 43.00k | 49.98 | 7.45 | 34.08 | 6.34 | 5.46 | 5.46 | 42.60 | 36.65 | 0.4985 | 1.71 | 6.61 | 377,814.00 | 6.39 | 7.32 | 7.37 | 8.72 | 63.87 | 65.69 | 12.82 | 13.78 | 1.32 | -- | 0.4797 | 39.73 | -3.58 | 7.61 | -23.24 | 2.13 | 12.52 | 16.25 |
| Intuitive Surgical, Inc. | 5.16bn | 1.62bn | 123.43bn | 8.08k | 77.50 | 11.36 | 63.17 | 23.91 | 13.38 | 13.38 | 42.61 | 91.30 | 0.461 | 2.66 | 8.54 | 638,893.70 | 14.63 | 13.99 | 16.06 | 15.59 | 68.69 | 68.84 | 31.74 | 28.80 | 5.42 | -- | 0.00 | 0.00 | -2.68 | 12.82 | -23.11 | 12.49 | 33.35 | -- |
| Medtronic PLC | 31.60bn | 3.88bn | 174.55bn | 90.00k | 45.23 | 3.39 | 26.40 | 5.52 | 2.87 | 2.87 | 23.36 | 38.29 | 0.3403 | 2.36 | 6.13 | 351,077.80 | 4.21 | 4.77 | 4.75 | 5.36 | 66.95 | 68.51 | 12.37 | 14.96 | 2.34 | 15.47 | 0.3345 | 60.93 | 4.16 | 0.8752 | -25.94 | -0.2157 | 5.31 | 8.83 |
| Holder | Shares | % Held |
|---|---|---|
| T. Rowe Price Associates, Inc. (Investment Management)as of 30 Jun 2021 | 8.97m | 7.54% |
| The Vanguard Group, Inc.as of 30 Jun 2021 | 8.70m | 7.31% |
| BlackRock Fund Advisorsas of 30 Jun 2021 | 5.24m | 4.40% |
| SSgA Funds Management, Inc.as of 30 Jun 2021 | 4.74m | 3.99% |
| Fidelity Management & Research Co. LLCas of 30 Jun 2021 | 4.03m | 3.39% |
| Capital Research & Management Co. (World Investors)as of 30 Jun 2021 | 3.62m | 3.04% |
| Edgewood Management LLCas of 30 Jun 2021 | 2.84m | 2.39% |
| Morgan Stanley Investment Management, Inc.as of 30 Jun 2021 | 2.24m | 1.88% |
| Geode Capital Management LLCas of 30 Jun 2021 | 2.00m | 1.68% |
| AllianceBernstein LPas of 30 Jun 2021 | 1.90m | 1.59% |
